{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+sublingual+tablet", "query": { "intervention": "Placebo sublingual tablet" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 66, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+sublingual+tablet&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-12T02:23:11.508Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03015246", "title": "Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Heroin Dependence", "Opioid Use Disorder" ], "interventions": [ { "name": "Extended release morphine", "type": "DRUG" }, { "name": "Buprenorphine/Naloxone low dose", "type": "DRUG" }, { "name": "Buprenorphine/Naloxone moderate dose", "type": "DRUG" }, { "name": "Buprenorphine/Naloxone high dose", "type": "DRUG" }, { "name": "Active stressor", "type": "DRUG" }, { "name": "Placebo stressor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wayne State University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 26, "start_date": "2016-12", "completion_date": "2020-08", "has_results": false, "last_update_posted_date": "2020-11-10", "last_synced_at": "2026-09-12T02:23:11.508Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03015246" }, { "nct_id": "NCT01110902", "title": "Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "Agomelatine (AGO178C)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 589, "start_date": "2010-05", "completion_date": "2011-06", "has_results": false, "last_update_posted_date": "2020-12-24", "last_synced_at": "2026-09-12T02:23:11.508Z", "location_count": 43, "location_summary": "Birmingham, Alabama • Costa Mesa, California • El Centro, California + 39 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Costa Mesa", "state": "California" }, { "city": "El Centro", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01110902" }, { "nct_id": "NCT03188185", "title": "A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "ALKS 5461", "type": "DRUG" }, { "name": "ALKS 5461 Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alkermes, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 278, "start_date": "2017-06-12", "completion_date": "2020-03-05", "has_results": true, "last_update_posted_date": "2021-04-08", "last_synced_at": "2026-09-12T02:23:11.508Z", "location_count": 30, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Los Alamitos, California + 27 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Oceanside", "state": "California" }, { "city": "Pico Rivera", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03188185" }, { "nct_id": "NCT02413281", "title": "A Study of the Abuse Liability Potential of ALKS 5461 in Healthy, Non-Dependent, Recreational Opioid Users", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "ALKS 5461", "type": "DRUG" }, { "name": "Buprenorphine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alkermes, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 56, "start_date": "2015-03", "completion_date": "2015-09", "has_results": false, "last_update_posted_date": "2015-11-10", "last_synced_at": "2026-09-12T02:23:11.508Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02413281" }, { "nct_id": "NCT02356588", "title": "A Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Operative Pain After Abdominal Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Post-Operative Pain" ], "interventions": [ { "name": "Sufentanil Tablet 30 mcg", "type": "DRUG" }, { "name": "Placebo Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Talphera, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 161, "start_date": "2015-02", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2017-02-13", "last_synced_at": "2026-09-12T02:23:11.508Z", "location_count": 4, "location_summary": "Sheffield, Alabama • Pasadena, California • Houston, Texas", "locations": [ { "city": "Sheffield", "state": "Alabama" }, { "city": "Pasadena", "state": "California" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02356588" }, { "nct_id": "NCT00303602", "title": "Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Schizophrenia", "Schizoaffective Disorder", "Bipolar Disorder" ], "interventions": [ { "name": "Sublingual orally disintegrating olanzapine (SODO)", "type": "DRUG" }, { "name": "Oral olanzapine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 149, "start_date": "2006-03", "completion_date": "2007-12", "has_results": true, "last_update_posted_date": "2009-06-10", "last_synced_at": "2026-09-12T02:23:11.508Z", "location_count": 7, "location_summary": "Escondido, California • Garden Grove, California • National City, California + 4 more", "locations": [ { "city": "Escondido", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "National City", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00303602" }, { "nct_id": "NCT02218008", "title": "A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "ALKS 5461", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alkermes, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 407, "start_date": "2014-07", "completion_date": "2016-10", "has_results": true, "last_update_posted_date": "2019-08-14", "last_synced_at": "2026-09-12T02:23:11.508Z", "location_count": 32, "location_summary": "Birmingham, Alabama • Colton, California • Garden Grove, California + 29 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Colton", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02218008" }, { "nct_id": "NCT04508621", "title": "A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Fibromyalgia" ], "interventions": [ { "name": "TNX-102 SL", "type": "DRUG" }, { "name": "Placebo SL Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tonix Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 514, "start_date": "2020-07-22", "completion_date": "2021-11-01", "has_results": true, "last_update_posted_date": "2023-12-18", "last_synced_at": "2026-09-12T02:23:11.508Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Oceanside, California + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Oceanside", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Ana", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04508621" }, { "nct_id": "NCT01677182", "title": "Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bipolar Disorder" ], "interventions": [ { "name": "Ramelteon", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 535, "start_date": "2012-08", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2016-03-16", "last_synced_at": "2026-09-12T02:23:11.508Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Anaheim, California • Glendale, California + 38 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Imperial", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01677182" }, { "nct_id": "NCT06480383", "title": "Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Generalized Anxiety Disorder" ], "interventions": [ { "name": "ITI-1284 10 mg", "type": "DRUG" }, { "name": "ITI-1284 20 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Intra-Cellular Therapies, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 705, "start_date": "2024-08-05", "completion_date": "2027-03-23", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-09-12T02:23:11.508Z", "location_count": 25, "location_summary": "Glendale, California • Imperial, California • Lemon Grove, California + 17 more", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Imperial", "state": "California" }, { "city": "Lemon Grove", "state": "California" }, { "city": "Oceanside", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06480383" } ] }